Suppr超能文献

瑞典针对40至49岁女性的乳腺癌检测新结果。

New Swedish breast cancer detection results for women aged 40-49.

作者信息

Tabar L, Duffy S W, Burhenne L W

机构信息

Department of Mammography, Central Hospital, Falun, Sweden.

出版信息

Cancer. 1993 Aug 15;72(4 Suppl):1437-48. doi: 10.1002/1097-0142(19930815)72:4+<1437::aid-cncr2820721405>3.0.co;2-m.

Abstract

The issue of whether to screen women aged 40-49 for breast cancer is debated usually in terms of the potential mortality reduction achievable by the application of screening in this age group. Theories regarding why a significant reduction in mortality has not been observed in trials relate to the biologic behavior of tumors in this age group and the screening process itself. Survival curves with respect to node status, size, and grade of the tumor were compared among age groups in the Swedish two-county trial. In the Kopparberg part of this trial, for the 40-49 age group, predicted survival was calculated from the size, node status, and grade of cancers detected during the trial in comparison with those found in two later series of tumors, one from the 1989-1992, Kopparberg screening program, the other from the British Columbia screening program, the other from the British Columbia screening program that began in 1988. The Kopparberg arm of the Swedish two-county study used single-view mammography with extended processing but without grid; the two more recent programs used two-view mammography with extended processing and the grid. Both the Kopparberg programs used a 2-year interval. The effects of grade, node status, and size on survival in the 40-49 age group were very similar to their effects in older age groups. Predicted survival from the latter Kopparberg series was essentially the same as that for the earlier. The mortality reduction in this age group in the Kopparberg part of the Swedish two-county trial was 26%. The survival results indicate no biologic reason why screening should not be able, theoretically, to reduce mortality. Nonsignificant reductions in mortality have been observed in the Kopparberg part of the two-county trial and in the overview of Swedish trials. The similar predictive results for the two-view and one-view trials suggest that the most likely way to achieve further reductions in mortality is to reduce the interval between screens, possibly to 1 year.

摘要

对于40至49岁女性是否进行乳腺癌筛查的问题,通常是围绕在该年龄组应用筛查所能实现的潜在死亡率降低来展开讨论的。关于为何在试验中未观察到死亡率显著降低的理论,涉及该年龄组肿瘤的生物学行为以及筛查过程本身。在瑞典两县试验中,对不同年龄组的肿瘤淋巴结状态、大小和分级的生存曲线进行了比较。在该试验的科帕尔贝里部分,对于40至49岁年龄组,根据试验期间检测到的癌症的大小、淋巴结状态和分级计算预测生存率,并与后来两个肿瘤系列中的情况进行比较,一个来自1989 - 1992年的科帕尔贝里筛查项目,另一个来自1988年开始的不列颠哥伦比亚筛查项目。瑞典两县研究的科帕尔贝里组使用单视图乳腺钼靶摄影并进行延长处理但无滤线栅;后两个项目使用双视图乳腺钼靶摄影并进行延长处理且有滤线栅。科帕尔贝里的两个项目都采用2年的间隔期。分级、淋巴结状态和大小对40至49岁年龄组生存的影响与对年龄较大组的影响非常相似。科帕尔贝里后一系列的预测生存率与早期的基本相同。瑞典两县试验中科帕尔贝里部分该年龄组的死亡率降低了26%。生存结果表明,从理论上讲,没有生物学原因说明筛查不能降低死亡率。在两县试验的科帕尔贝里部分以及瑞典试验综述中,观察到死亡率有不显著的降低。双视图和单视图试验相似的预测结果表明,实现死亡率进一步降低的最可能方法是缩短筛查间隔,可能缩短至1年。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验